Navigation Links
ViroPharma in Medical News

Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma

- Michel de Rosen to Continue as Chairman of the Board of Directors; Daniel B. Soland Promoted to Chief Operating Officer - EXTON, Pa., Feb. 26 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM ) announced today that, effective March 31, 2008, Vincent J. Milano will suc...

ViroPharma Announces Initiation Of Non-Toxigenic Clostridium Difficile Phase 1 Program

... EXTON, Pa., Aug. 6 /PRNewswire-FirstCall/ -- viropharma Incorporated (Nasdaq: VPHM ) today announced tha...nitis and perforation of the colon. About viropharma Incorporated viropharma Incorporated is a biopharmaceutical company dedica...

ViroPharma Announces Support by Advisory Committee of The Office of Generic Drugs Proposed Guidelines for Developing Generic Versions of Oral Vancomycin Hydorchloride

...TON, Pa., Aug. 4 /PRNewswire-FirstCall/ -- viropharma Incorporated (Nasdaq: VPHM ) today announced tha...BE rather than using comparative clinical trials. viropharma scientists and other leading experts voiced their ...onitis and perforation of the colon. About viropharma Incorporated ...

ViroPharma Incorporated Reports Second Quarter 2009 Financial Results

... EXTON, Pa., July 29 /PRNewswire-FirstCall/ -- viropharma Incorporated (Nasdaq: VPHM ) reported today its ... million. Looking ahead in 2009 viropharma is revising its guidance for the year 2009. The following guidance provided by viropharma are projections, based upon numerous assumptions, ...

ViroPharma to Release 2009 Second Quarter Financial Results on July 29, 2009

... EXTON, Pa., July 14 /PRNewswire-FirstCall/ -- viropharma Incorporated's (Nasdaq: VPHM ) second quarter fi...Time on the same day. During the conference call, viropharma management will discuss the 2009 second quarter an...all, please tell the operator you wish to join the viropharma investor conference call. About...

Changing Paradigms in Hereditary Angioedema: A Focus on Timely Diagnosis and New Therapies

... Changing Paradigms in Hereditary Angioedema: A Focus on Timely Diagnosis and New Therapies . This activity is supported by an educational grant from viropharma Incorporated. Faculty for this continuing medical education activity include the following experts in allergy and immunology: Allen P. Kaplan, MD...

Changing Paradigms in Hereditary Angioedema: Pathophysiology, Diagnosis and Treatment

...rived from a live symposium which took place on February 13, 2009 in Fort Lauderdale, Florida. This activity is supported by an educational grant from viropharma Incorporated and is accredited for physicians. Faculty reviewers include Michael M. Frank, MD from Duke University School of Medicine in Durham...

New Directions in Angioedema: A Focus on Etiologies and Clinical Approach

...ned to assist physicians and nurses in understanding the etiology and diagnosis of angioedema. This activity is supported by an educational grant from viropharma Incorporated. Timothy J. Craig, DO, Professor of Medicine and Pediatrics at the Pennsylvania State University College of Medicine in Hershey, P...

ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors

... EXTON, Pa., June 8 /PRNewswire-FirstCall/ -- viropharma Incorporated (Nasdaq: VPHM ) today announced the...rom his guidance and his experience. He brings to viropharma a wealth of experience in virtually any issue that...for NicOx, S.A., and Acusphere, Inc. About viropharma Incorporated ...

ViroPharma Announces Meeting of FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology on Bioequivalence Recommendations for Oral Vancomycin Hydrochloride Products

...tonitis and perforation of the colon. About viropharma Incorporated viropharma Incorporated is a biopharmaceutical company dedica...by physician specialists and in hospital settings. viropharma commercializes Vancocin(R), approved for oral admi...
ViroPharma in Medical Technology

Scientific Data Relating to Cinryze(TM) Presented at 6th Annual C1 Inhibitor Deficiency Workshop

...y and EXTON, Pa., May 26 /PRNewswire-FirstCall/ -- viropharma Incorporated (Nasdaq: VPHM ) today announced the...tacks in adults and adolescents. In February 2009, viropharma was granted priority review of a supplemental Biol...potential for subcutaneous infusion, among others, viropharma is demonstrating our commitment to meeting the nee...

ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance

... EXTON, Pa., March 18 /PRNewswire-FirstCall/ -- viropharma Incorporated (Nasdaq: VPHM ) today announced its... use of OGD's proposed new BE method for Vancocin, viropharma also believes that, even if the new method was val...tandard. Unless those products are reformulated, viropharma believes they should not possess "comparable disso...

Changing Paradigms in Hereditary Angioedema: A Focus on Prompt Diagnosis and New Therapies

...tivity, titled Changing Paradigms in Hereditary Angioedema: A Focus on Prompt Diagnosis and New Therapies, is supported by an educational grant from viropharma Incorporated and is accredited for physicians, nurses, and pharmacists. The faculty for these lectures comprises experts in immunology and HAE fr...

ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients

... EXTON, Pa., Feb. 13 /PRNewswire-FirstCall/ -- viropharma Incorporated (Nasdaq: VPHM ) today announced tha...w suppression and renal impairment. About viropharma Incorporated viropharma Incorporated is a biopharmaceutical company dedica...

FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)

... EXTON, Pa., Feb. 3 /PRNewswire-FirstCall/ -- viropharma Incorporated (Nasdaq: VPHM ) today announced tha...ciation's website at: www.haea.org . About viropharma Incorporated viropharma Incorporated is a biopharmaceutical company dedica...

ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema

... - EXTON, Pa., Nov. 12 /PRNewswire-FirstCall/ -- viropharma Incorporated (Nasdaq: VPHM ) today announced the ...ation's website at: http://www.haea.org . About viropharma Incorporated viropharma Incorporated is a biopharmaceutical company dedica...

ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals

... - EXTON, Pa., Oct. 21 /PRNewswire-FirstCall/ -- viropharma Incorporated (Nasdaq: VPHM ) today announced it h...ers will receive $2.25 in cash, 0.042146 shares of viropharma common stock and one non- transferable contingent ...ev common stock that they own. The total number of viropharma shares to be issued as part of the merger consider...

Current Concepts in Clostridium difficile Infection: A Focus on Recurrent Disease

...is jointly sponsored by Robert Michael Educational Institute LLC and Postgraduate Institute for Medicine and is supported by an educational grant from viropharma Incorporated. Robert Michael Educational Institute LLC is a full-service medical education company dedicated to providing comprehensive medical educ...

ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients

...s - EXTON, Pa., May 29 /PRNewswire-FirstCall/ -- viropharma Incorporated (Nasdaq: VPHM ) today announced that...e marrow suppression and renal impairment. About viropharma Incorporated viropharma Incorporated is a biopharmaceutical company dedica...

ViroPharma Announces Discontinuation of HCV-796 Development

... EXTON, Pa., April 16 /PRNewswire-FirstCall/ -- viropharma Incorporated (Nasdaq: VPHM ) announced today that viropharma and Wyeth Pharmaceuticals, a division of Wyeth (NY...t standard of care. ViroPharma also announced that viropharma and Wyeth do not expect to continue to collaborate...
ViroPharma in Biological Technology

Clostridium difficile Infection: Strategic Approaches for Better Outcomes

...uing education lectures conveniently located at medical institutions across the United States. This activity is supported by an educational grant from viropharma Incorporated and is accredited for physicians, pharmacists, and registered nurses. Faculty for these lectures are leading experts in infectious d...

ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema

... EXTON, Pa., June 4 /PRNewswire-FirstCall/ -- viropharma Incorporated (Nasdaq: VPHM ) today announced tha...Cinryze in the clinical studies. In addition, viropharma announced that FDA has approved the patient labeli...iation's website at: www.haea.org . About viropharma Incorporated ...

ViroPharma to Present at Two June Healthcare Conferences

... EXTON, Pa., June 2 /PRNewswire-FirstCall/ -- viropharma Incorporated (Nasdaq: VPHM ) today announced tha...ing held at the Grand Hyatt in New York City. viropharma also announced that William Roberts, vice presiden...of 14 days following the conferences. About viropharma Incorporated ...

ViroPharma Incorporated Honored by the National Organization for Rare Disorders

... EXTON, Pa., May 18 /PRNewswire-FirstCall/ -- viropharma Incorporated (Nasdaq: VPHM ) was honored with a ... "but what is even more gratifying for everyone at viropharma is making a difference in the lives of HAE patient...tacks in adults and adolescents. In February 2009, viropharma was granted priority review of a supplemental Biol...

ViroPharma Incorporated Reports First Quarter 2009 Financial Results

... EXTON, Pa., April 29 /PRNewswire-FirstCall/ -- viropharma Incorporated (Nasdaq: VPHM ) reported today its ...$9.2 million. Looking ahead in 2009 viropharma is reiterating its guidance for the year 2009 as a... to investors. The following guidance provided by viropharma are projections, based upon numerous assumptions, ...

ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009

... EXTON, Pa., April 22 /PRNewswire-FirstCall/ -- viropharma Incorporated's (Nasdaq: VPHM ) first quarter fin...Time on the same day. During the conference call, viropharma management will discuss the 2009 first quarter and...all, please tell the operator you wish to join the viropharma investor conference call. About...

ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes

... EXTON, Pa., March 24 /PRNewswire/ -- viropharma Incorporated (Nasdaq: VPHM ) announced it has re... As a result of the convertible note repurchase, viropharma expects that its fully diluted shares outstanding ...nancial statements for the first quarter of 2009. viropharma anticipates that the taxable gain arising from the...

ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results

... EXTON, Pa., Feb. 24 /PRNewswire-FirstCall/ -- viropharma Incorporated (Nasdaq: VPHM ) reported today its ...for maribavir, 2008 was a very successful year for viropharma -- from strong financial results to great executio... of $2.25 per share in cash and $0.50 per share in viropharma common stock, and contingent consideration (CVRs) ...

Clostridium difficile Infection: Current Challenges and Controversies

...and nurses titled Clostridium difficile Infection: Current Challenges and Controversies. This activity is supported by an educational grant from viropharma Incorporated. The information contained in this virtual lecture and podcast was originally presented as a live symposium during the 2008 ICAAC/...

ViroPharma to Present at Three November Healthcare Conferences

... EXTON, Pa., Nov. 6 /PRNewswire-FirstCall/ -- viropharma Incorporated (Nasdaq: VPHM ) today announced that...ence is being held at the New York Palace Hotel. viropharma also announced that Colin Broom, vice president, chief scientific officer of viropharma will present at the Lazard Capital Markets 5th Ann...
Other Tags
(Date:9/1/2015)... ... 2015 , ... A new episode of “Voices In America”, hosted by famous ... topic of arthritis. There are over 100 different types of arthritis. One of the ... in an effort to shed light on this important topic. , Anyone who is ...
(Date:9/1/2015)... ... , ... The premier online medical education company for Podiatrists ... podiatric, surgical and wound care conferences . The Residency Education Summits standardize ... the podium and across the table during hands-on surgical and advanced wound care ...
(Date:8/31/2015)... Orange, NJ (PRWEB) , ... September 01, 2015 ... ... the spine to eliminate chronic back pain – once required a long, arduous ... a shorter hospital stay, less pain, less blood loss and minimal muscle damage. ...
(Date:8/31/2015)... ... August 31, 2015 , ... ITC ... wealth of information for specific translation services within the medical and pharmaceutical industries. ... track record of successful work. , ITC Global Translations specializes in professional translation ...
(Date:8/31/2015)... ... , ... In an article based on a reader’s question that ... of treating back pain caused by a disrupted disk by using steroids rather than ... function in patients suffering from a herniated disk, the level of pain that patients ...
Breaking Medicine News(10 mins):Health News:PRESENT e-Learning Systems Announces their 2016 Podiatry and Wound Care Medical Education Conference Schedule 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 3Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 4Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 2Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 3Health News:Article on Steroid Use for Back Pain Highlights the Effectiveness of Surgery in Treating Disk Pain, says Dr. Seyed M. Rezaian 2
(Date:8/4/2015)... N.Y., Aug. 4, 2015  AMRI (NASDAQ: AMRI ) today ... 30, 2015. Highlights: , Second quarter contract ... from 2014 , Adjusted contract margins of ... of $0.22, including a $0.05 decrease in EPS from royalties in ... $16 million "We are very pleased to present ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julio de 2015 ... sobre Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 ... . La conferencia celebra su décimo ... se ha convertido en una de las reuniones anuales ... ,ómicas, y es una de las conferencias científicas más ...
(Date:7/31/2015)... julio de 2015 La 10 th International ... medio de BGI del 22 al 25 de octubre de 2015 ... Este año, la conferencia celebra su décimo aniversario. Desde su ... una de las reuniones anuales más influyentes del mundo en ... más dinámicas, entusiastas y mejores a nivel científico. ...
Breaking Biology News(10 mins):AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
Other Contents